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Poster Session II S351Materials and Methods: We retrospectively analyzed all patients
(n 5 64) from January 1, 2009 to December 31, 2009 at our institu-
tion undergoing allogeneic SCT for hematologic malignancies. PLT
refractoriness was defined as a clinical requirement for platelet cross-
matching. Clinical outcomes studied included day 100 and one year
survival, platelet and neutrophil engraftment and acute GVHD inci-
dence. Risks of death and GVHD were compared between groups
with logrank tests and were estimated with the Kaplan-Meier
method. Number of days to platelet or neutrophil engraftment was
compared with the Wilcoxon rank-sum test.
Results: Allogeneic SCT was performed in 64 patients including
three pediatric patients. 10/64 (16%) patients demonstrated PLT re-
fractoriness. Patients with PLT refractoriness had higher risk of
acute GVHD (Grade I-IV) as compared to non refractory patients
(p 5 0.046). Excluding patients without platelet engraftment due
to early death, patients with pretransplant PLT refractoriness (n 5
9) had delayed PLT engraftment, median (IQR) 5 27 days (19.5-
64.50) compared to non-refractory patients (n 5 52), median
(IQR) 5 19 days (16-23) (p 5 0.01). However, there was no signifi-
cant differences in terms of overall survival, GVHD grade II-IV or
time to neutrophil engraftment
Conclusions: PLT refractoriness may be associated with increased
incidence of acute GVHD and delayed platelet engraftment result-
ing in longer platelet transfusion support. A larger study is planned
to confirm these findings.397
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Radiotherapy (RT) is used as an antineoplastic and immunomod-
ulatory therapy prior to allogeneic HCT. The practice of incorpo-
rating RT as part of HCT varies widely across centers worldwide.
The present study explores the use of RT in 14,920 allogeneic
HCT recipients (total body irradiation [TBI], N5 14,696, and total
lymphoid irradiation [TLI], N5 402) reported to the Center for In-
ternational Blood and Marrow Transplant Research between 1995
and 2010. TBI was performed in 335 reporting centers in 42 coun-
tries. The median age of TBI recipients was 33 years and the median
age increased from 31 to 39 years during the period (p\0.0001). TBI
was most commonly use in HCT for acute lymphocytic leukemia
(87%) and in patients with prior central nervous system (CNS) leu-
kemia involvement (76%, p\0.001). Shielding was used in 52% of
patients, commonly for lungs (72%) and eyes (14%). The median
dose of TBI was 12 Gy, with most patients receiving 2 fractions
per day (60%, p\0.0001), for total of 6 doses (34%, p\0.0001).
Myeloablative TBI doses (.8 Gy) decreased from 94% to 63% dur-
ing the period (p\0.001). Conversely, reduced intensity and non-
myeloablative (RI/NMA) TBI doses increased from\1% to 36%
(p\0.001). TBI was most frequently combined with cyclophospha-
mide (97%) in myeloablative regimens and fludarabine (68%) in
RI/NMA regimens. 11% of patients who received TBI also received
RTwithin 14 days of starting conditioning; treatmentwas directed at
the CNS (35%) and gonads (41%). TLI was performed in 70 centers
in 22 countries. The median age for TLI recipients was 37 years and
the median age increased from 29 to 56 years during the period. The
most common indications for TLI was severe aplastic anemia (SAA)
(23%) and acute myeloid leukemia (AML) (19%). TLI for SAA de-
creased from 47% to 0% while TLI for AML increased from 11%to 40% during the period. The median TLI dose was 6 Gy, with
most patients receiving 6 fractions (41%). 4% of patients who re-
ceived TLI also received RTwithin 14 days of starting conditioning;
treatment was most often directed at the spleen (47%). RT practices
in HCT changed during the past 16 years. There was a significant
decrease use of myeloablative TBI and increase in RI/NMA TBI.
Similarly, TLI practices changed towards a RI/NMA approach, be-
ing applied more frequently in older patients for treatment of malig-
nant diseases.
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PREDICTIVE FACTORS FOR ADVERSE OUTCOMES AFTER USE OF DONOR
CELL INFUSION (DCI) IN PATIENTS WITH RELAPSED HEMATOLOGICAL
MALIGNANCIES TREATED WITH ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (AlloHCT)
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DCI is administered after AlloHCT to enhance the graft-versus
leukemia effect and thereby induce remission in patients (pts) with
relapsed hematological malignancies. The purpose of this retrospec-
tive study was to identify risk factors for post-DCI progression and
mortality.
We identified 47 pts with hematological malignancies who re-
ceived DCI from 02/1996 to 07/2011 for disease relapse. We ana-
lyzed variables such as pts baseline demographics, malignancy
type, donor relationship, type of AlloHCT, presence of GVHD, du-
ration of post-transplant remission, use of remission induction che-
motherapy prior to DCI and DCI cell dose.
Among pts treated with DCI, 36 (77%) hadmyeloidmalignancies.
Myeloablative regimen was used in 36 pts (77%) and 35 pts (74%)
had HLA-identical sibling donor transplant. 45 pts (96%) had grade
\2 aGVHD and 40 pts (85%) had limited or no cGVHD. Median
time of post-transplant relapse was 6.0 months (range, 0.9-84.6)
and the median time from transplant to DCI therapy was 7.8 months
(range, 2.3- 114). DCI was used once in 89% of pts and it was pre-
ceded with chemotherapy in 35 of 45 pts (78%). Median CD34
and TNC doses for the first DCI were 2.0x106 and 3.9x108 respec-
tively. The rate of post-DCI grade 3-4 aGVHD was 2% vs. 17%
for extensive cGVHD. With a median follow-up of 40.8 months
(range, 2.3-174.1), 38 pts (77%) had died and 29 (62%) relapsed. Re-
lapse was the most common cause of death (n5 25, 69%) after DCI.
Although pts who received unrelated DCI tended to have less post-
DCI relapses (42% vs. 69%), deaths (50% vs. 86%) or fatal events
due to relapse (50% vs. 73%), the numbers were too small to detect
statistically significant differences between groups. Recursive parti-
tioning analysis indicated that pts who had disease relapse within
20 months after transplant (n 5 39) were at higher risk of post-
DCI relapse, worse OS and RFS. Multivariable analysis demon-
strated that a bone marrow cell source was associated with poor
OS (HR 5 2.6; 95% CI 1.3-5.6, p 5 0.01) compared to peripheral
blood, and that post-transplant disease relapse within 20 months
was an adverse predictor for post-DCI relapse (HR 5 5.2; 95% CI
1.2-22.3, p 5 0.025), OS (HR 5 5.5; 95% CI 1.6-18.5, p 5 0.006)
and RFS (HR 5 3.5; 95% CI 1.2-9.9, p 5 0.02).
With long follow-up we demonstrated that disease relapse within
20months of AlloHCTportends poor clinical outcome despiteDCI,
but for patients with longer remission duration, DCI can result in
long-term progression free survival.
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ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN ADULT ALL PA-
TIENTS IN CR1: RESULTS OF UNRELATED DONORS ARE COMPARABLE
TO SIBLING DONORS?
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In the German Multicenter ALL Studies, patients (pts) with Ph+
ALL (very high risk, VHR), with high risk ALL (HR), e.g. B lineage
S352 Poster Session IIALL with leukocytes .30/nl at diagnosis and/or delayed CR (.4
weeks), pro B-ALL or complex karyotype, T lineage ALL (prae T-
ALL, mature T-ALL) and standard risk ALL (SR-ALL) with molec-
ular persistence or relapse are candidates for SCT in CR1. Pts with
siblings have a 25% probability (prob) of an HLA identical sibling.
Pts without an HLA identical sibling have a chance of 80% to find
a compatible unrelated donor.
Here, we report our single centre data on SCT from sibling and
unrelated donors. High resolution HLA typing class I+II was done
since 01/2006. Between 2006 and 2010, 36 pts with ALL, CR1 un-
derwent SCT. 12 pts had a sibling donor, 14 pts an HLA identical
unrelated donor (MUD) and 10 pts an HLA compatible unrelated
donor (MMUD). All HLA mismatches were in class I, 9/10 pairs
had 1 mismatch (HLA-C antigen 4, HLA-A antigen 3, HLA-B allele
2) and 1/10 pairs had 2 mismatches (HLA-C antigen and HLA-B al-
lele). Median age was 43 (18-67) years (yrs), not different between
sibling or unrelated SCT. Indication for SCT: 14/36 pts belonged
to the VHR group, 19/36 pts to the HR group and 3/36 pts of the
SR group had molecular relapse. All pts were transplanted in CR1
(bone marrow \5% blasts). Conditioning was myeloablative
(MAC) in 30/36 pts (12 Gy TBI and VP 16 or CY 29, other 1) and
in 6/36 pts reduced intensity (RIC). Pts with unrelated donors re-
ceived antithymocyte globuline (ATG) (60mg/kg in MAC, 40mg/
kg in RIC).
Results: 25/36 pts are alive in CR (median f/u 40 months, 7-66), 11/
36 pts died 8 months (0.5-24) after SCT. Causes of death: leukemia
3, infection6GvHD 6, other 2. Prob of OS for all pts (36) at 4 yrs is
0.65, 0.82 for SCT with sibling donors, 0.52 for MUD-SCT, 0.56
for MMUD-SCT. The differences were not significant. Prob of
LFS is 0.59 for all pts, in pts with sibling donors 0.82, after MUD-
SCT 0.49 and 0.44 after MMUD-SCT. Prob of NRM for all pts
was 0.26, in sibling SCT 0.18, in MUD-SCT 0.34 and in
MMUD-SCT 0.26.
Conclusion: In ALL, CR1 SCT afterMAC and with a sibling donor
is still the gold standard (OS 0.82). In unrelated donor SCTwe found
no difference in survival between HLA identical or 1 antigen mis-
matched donor-recipient pairs. It has to be discussed if dose reduc-
tion of ATG in MUD-SCT might improve the results by
decreasing NRM and relapse post SCT.400
NONABLATIVE CONDITIONING REGIMEN FOR CD20+ B-CELL LYM-
PHOID MALIGNANCIES: SHOULD CONDITIONING REGIMENS BE INDI-
VIDUALIZED TO OPTIMIZE TRANSPLANT OUTCOME?
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Background:Allogeneic stem cell transplantation (allo-SCT) is lim-
ited by transplant-related-mortality (TRM), primarily mediated by
graft-versus-host disease (GVHD). Disease specific preparative reg-
imens that offer acceptable graft-versus-host disease (GVHD)-asso-
ciated morbidity and TRM are preferred. The B-cell lymphoma
specific nonablative (NST) regimen fludarabine, cyclophosphamide
and rituximab (FCR) is reportedly safe and effective, however most
reported data are from single institution.
Methods: Twenty six pts with recurrent CD20+ B-cell lymphoid
malignancies received FCR NST allo-SCT between March 2008
and May 2011. The conditioning regimen consisted of fludarabine
(30 mg/m2 daily for 4 days), cyclophosphamide (750 mg/m2 daily
for 3 days) and rituximab (375 mg/m2, day-13,-6,+1,+8). This was
followed by either related (n 5 18) or unrelated donors (n 5 8)
allo-SCT. All patients received tacrolimus and mini-methotrexate
GVHD prophylaxis (rATG for unrelated donor allo-SCT).
Results: The median age of pts at transplantation was 59 years
(range 41-64). Ten pts had CLL, 7 MCL, 3 DLBCL, 3 FL and 3
transformed-lymphoma. At diagnosis, 20 (77%) pts had stage IV dis-
ease. Twenty three pts (88%) received $3, 14 (54%) $4 regimens
and 4 (15%) had prior autologous-SCT. Nine (35%) pts were in
complete remission pre-SCT following salvage therapy. At the
time of analysis, 17 pts were alive with an estimated 2-year OS and
PFS of 63%, and non-relapse mortality (NRM) 25%. Grade II-IV
aGVHD occurred in 8 (31%) pts and chronic GVHD in 6 (24%)pts (extensive 5 3). Causes of death includes progressive disease 4,
aGVHD2 (both after receivingDLI formixed chimerismwith resid-
ual disease), infection 1 and others 2 (substance abuse, leucoence-
phalopathy). Only 6 pts required re-hospitalization within 100
days of SCT, (average 10 days; range, 3-18).
Conclusion: Our data suggests nonablative FCR conditioning reg-
imen is safe and effective in heavily pre-treated B-cell lymphoid ma-
lignancies. While our conclusion is limited by the small sample size,
this suggests the need for larger prospective studies to validate the ef-
ficacy of FCR and to compare it with other reduced-intensity condi-
tioning allo-SCT in B-cell malignancies. We recommend that FCR
allo-SCT be considered early and novel strategies (radioimmuno-
therapy, tandem auto-allo-SCT) be incorporated and evaluated to
major cause of failure, particularly in heavily pre-treated pts.401
EBV-POSITIVE LYMPHOPLASMACYTIC LYMPHOMA: A HIGHLY AGGRES-
SIVE POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH
MULTIORGAN INVOLVEMENT
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ter, Providence, RI; 2Boston University School of Medicine, Boston, MA
Post transplant lymphoproliferative disorder (PTLD) is a hetero-
geneous disease ranging from benign polyclonal proliferation of B
cells to monoclonal B cell proliferation. Its cumulative incidence is
about 1% with most cases observed during the first year. Most cases
are associated with Epstein-Barr virus (EBV) infection. Indolent
lymphomas are not considered part of PTLD in the WHO 2008
classification.
Here we describe two cases of EBV related post transplant lym-
phoplasmacytic lymphoma (LPL) with multiorgan failure and ag-
gressive course. The first patient was an EBV positive 28-year old
male with refractory Hodgkin’s lymphoma following autologous
transplant. The second was an EBV negative 57-year old male
with relapsed peripheral T-cell lymphoma, otherwise non-specified.
They underwentmatched unrelated allogeneic transplant after being
conditioned with fludarabine, busulfan and ATG. They received
methotrexate and cyclosporine for GVHD prophylaxis. On Day
+20 post transplant, the first patient presented with fever, nausea, di-
arrhea, and bilateral cervical lymphadenopathy. He had pancytope-
nia, elevated liver enzymes, and acute renal failure. Bone marrow
aspirate and biopsy findings were consistent with monomorphic
LPL with normal cytogenetics. Biopsies of a cervical lymph node,
duodenum and a colonic mass revealed the same histology. Serum
protein immunofixation (SPIF) showed biclonal IgG kappa and
lambda, IgA kappa and biclonal IgM lambda gammopathy. EBV
PCRwas 0.597x106 copies/ml.Hewas treated with immunosuppres-
sion tapering, cyclophosphamide and rituximab with no evidence of
improvement. The second patient presented with fever on day +35
post transplant. He had cervical, retroperitoneal and inguinal lymph-
adenopathy, splenomegaly, as well as pancytopenia, elevated liver
enzymes and acute renal failure. Bonemarrow aspirate and biopsy re-
vealed a monomorphic LPL. SPIF showed biclonal IgG kappa para-
protein with lambda chains. EBV PCR was 1.38x106 copies/ml. He
was treated with immunosuppression tapering and rituximab but his
condition deteriorated rapidly.
We described two cases of EBV driven post transplant LPL with
profound protein abnormalities and multiorgan failure despite indo-
lent morphology. Although indolent lymphomas are not considered
part of PTLD, clinicians must be aware of this presentation. Severity
of cases and lackof response to treatment should further bring intodis-
cussion the role of EBV load regular monitoring in patients at risk.402
SENSITIVE REAL-TIME PCR CHIMERISM ASSAY FOR HSCT MONITORING
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Chimerism testing, or themeasurement of the percent of recipient
and donor hematopoietic cell origin, is a standard of care for HSCT
recipients. For leukemic recipients, the quantification of chimerism
